Gefässchirurgie
Journal Abbreviation: GEFASSCHIRURGIE
ISSN: 0948-7034
eISSN: 1434-3932
Publisher: Springer Verlag
Publications (35)
Predicting major bleeding events in patients with peripheral arterial disease: the OAC(3)-PAD risk score (2022)
Behrendt CA, Rother U, Uhl C, Goertz H, Stavroulakis K, Gombert A
Journal article
Die Wahrnehmung der peripheren arteriellen Verschlusskrankheit (PAVK) als Volkskrankheit: Behandeln wir nur die Spitze eines riesigen Problems? (2022)
Behrendt CA, Uhl C, Görtz H, Marchiori E, Dovhanskiy D, Stavroulakis K, Rümenapf G, et al.
Journal article
Recommendations on conservative therapy and secondary prevention of peripheral arterial disease (PAD): an evidence-based information brochure for sufferers (2021)
Rosenberg Y, Goertz H, Rother U, Uhl C, Stavroulakis K, Pfeiffer M, Pfeiffer-Krahl M, Behrendt CA
Journal article
Erratum zu: Die Epidemiologie der peripheren arteriellen Verschlusskrankheit und deren sozioökonomische Bedeutung – Synopse (2021)
Calo P, Corvalan J, Behrendt CA, Böckler D, Rümenapf G, Rother U, Uhl C, Görtz H
Journal article, Erratum
Chronic critical limb ischemia in octogenarian patients Advantages and disadvantages of endovascular and surgical procedures (2021)
Uhl C, Behrendt C, Goertz H, Ruemenapf G, Boeckler D, Rother U
Journal article
Gemeinsam klug entscheiden – Diabetisches Fußsyndrom (2021)
Uhl C, Heller A, Rother U, Hatzl J, Böckler D
Journal article, Review article
Die Epidemiologie der peripheren arteriellen Verschlusskrankheit und deren sozioökonomische Bedeutung – Synopse (2021)
Calo P, Corvalan J, Behrendt CA, Boeckler D, Ruemenapf G, Rother U, Uhl C, Goertz H
Journal article, Review article
Exercise training for intermittent claudication: critical analysis (2020)
Rumenapf G, Rother U, Behrendt C, Uhl C, Gortz H, Morbach S, Sigl M
Journal article
The relevance of the "angiosome" concept for treatment of chronic limb-threatening ischemia (2020)
Rother U, Günther J, Meyer A, Lang W, Behrendt C, Gortz H, Rumenapf G, Uhl C
Journal article
Randomized controlled trials and real-world evidence for market access and surveillance of high-risk products—The example of paclitaxel (2020)
Behrendt C, Rother U, Rümenapf G, Uhl C, Görtz H, Böckler D
Journal article, Review article